**关于征集**《**同济医学院海外校友精选科研论文集**》**2017版论文的通知**

亲爱的同济医学院海外校友，

您好，

正如同济医学院海外校友总会向惠云主席所言，“同济医学院有众多海外校友，他们在许多领域都有杰出的成就，限于他们的英文学术论文发表在不同领域的学术期刊上，如果不加征集以及编辑，就会像黄金一样埋没在汪洋大海的沙底里面。另外，很多文献如果不在当年收集，多年以后就再也找不着了。很难想象，20-30年后我们还能像今天比较容易地征集海外校友的精选论文，很多恐怕连名字都无法与同济医学院联系上了。”

因此，校友总会从2007年起开始每年出版[《同济医学院海外校友精选科研论文集》](http://www.xiahepublishing.com/Books.aspx?sid=2)（简称《论文集》），向惠云、李国华、李孟荣, 沈四九和刘恒意一起负责了征集和编辑工作。自2013年起，每年[《论文集》](http://www.xiahepublishing.com/Books.aspx?sid=2)的征集以及编纂工作由以夏华向为主编的编委会主持。2013年、2014年和2015年版《论文集》分别收到来自34、14和20位校友的77、38和48篇论文。每年，[《论文集》](http://www.xiahepublishing.com/Books.aspx?sid=2)分别由校友总会负责人赠送给同济医学院及附属医院，并由同济医学院图书馆收藏。2017年，正值同济医学院建院110周年之际，海外校友总会郑重地向同济医学院院长赠送了收入31位校友91篇论文的2016年版《论文集》，作为献给母校的生日厚礼！

在此，我们真诚地邀请您提交您本人自2016年至今在国际知名杂志上发表的有代表性的论文，最好选择以第一或通讯作者发表的原著（篇数不限，但请不要提交已收入以往[《论文集》](http://www.xiahepublishing.com/Books.aspx?sid=2)的论文。）。与此同时，我们也希望您向您认识的所有在海外从事科研和学术的校友转达该通知。鉴于版权问题，同时考虑扩大收集量，从2014年版起，只需提交论文提交表（附录一），无需提交论文全文。

另外，为增加读者对校友的了解，我们希望校友同时提供简单的自我介绍（附录二）。

收稿截止日期为**2017年9月30日。**

**请在此截止日期前将论文提交表（附录一）以及个人简介（附录二）送夏华向和谢玲琳**。

历年[《论文集》](http://www.xiahepublishing.com/Books.aspx?sid=2)请参见华誉出版社网站(<http://www.xiahepublishing.com/Books.aspx?sid=2>).

如有任何意见和建议，敬请联系我们。感谢校友的支持！

**《同济医学院海外校友精选科研论文集2015-2016》编辑委员会**

夏华向xiaharry@hotmail.com

谢玲琳linglin.xie@tamu.edu

沈世乾shiqianshen@gmail.com

汪尔佳 erjiawangmd@gmail.com

沈四九shensijiu@gmail.com

向惠云 Huiyun.Xiang@nationwidechildrens

2017年8月15日

**附录一**

**论文提交表示例（参照PubMed格式）**

***论文一***

**论文题目（Copy from PubMed or the full-text）：**

Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3

**作者及其单位和联系信息（Copy from PubMed or the full-text）**：

Yuan-Yuan Zhanga, Jin-Nan Lib, Harry Hua-Xiang Xiac, Shi-LunZhangb, Jiang Zhongb, Yi-Ying Wua, Shi-Kun Miaoa, Li-Ming Zhoua, aDepartment of Pharmacology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, China；bDepartment of Microbiology, School of Life Sciences, Fudan University, Shanghai, 200433, China；cNovartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07039, USA

**杂志及论文出版信息（Copy from PubMed or the full-text）：**

Life Sci. 2013 Jul 10;92(24-26):1186-94. doi: 10.1016/j.lfs.2013.05.010. Epub 2013 May 20.

**论文摘要（Copy from PubMed or the full-text，如没有摘要，可略此项）**：

AIM:

To investigate whether losartan has protective effects in mice with chronic viral myocarditis induced by coxsackievirus B3 (CVB3).

MAIN METHODS:

Thirty two male Balb/c mice were intraperitoneally injected with CVB3 (10×TCID50) to induce chronic viral myocarditis (CVM). Losartan at 12.5mg/kg (n=16) or normal saline (n=16) were orally administered daily for 28 days to these mice. Uninfected mice (n=6) were used as controls. On day 29, all mice underwent anesthesia and echocardiography prior to sacrifice. Serum IL-17, IL-4, IFN-γ and TNF-α levels were measured by enzyme-linked immunosorbent assay, and cardiac tissues were histologically examined after hematoxylin & eosin staining. In addition, the effect of losartan on the virus titers in primary cultured neonatal rat cardiomyocytes infected with CVB3 was measured on Hep-2 cells at 72 h post infection.

KEY FINDINGS:

Mice infected with CBV3 had significantly increased mortality, heart/body weight ratios, necrosis and inflammatory scores and decreased cardiac ejection fractions, compared with the controls (all P<0.05). Losartan significantly decreased mortality from 40.0% to 12.5%, heart/body weight ratios from 7.08 ± 2.17 to 4.15 ± 0.99, and necrosis and inflammatory scores from 3.33 ± 0.50 to 2.50 ± 0.65 (all P<0.05), and increased ejection fractions from 55.80 ± 9.25 to 72.31 ± 12.15 (P<0.05). Losartan significantly enhanced IL-4, and decreased IFN-γ, TNF-α and IL-17 (all P<0.05). In the in vitro experiment, losartan had no influence on virus titers.

SIGNIFICANCE:

Losartan protects mice against CVB3-induced CVM, most likely through upregulating Th2 responses, and down-regulating Th1 and Th17 responses.

Copyright © 2013 Elsevier Inc. All rights reserved.

**PubMed链接（Copy from PubMed）**：

<http://www.ncbi.nlm.nih.gov/pubmed/23702425>

**论文全文链接（Copy from journal’s website）**：<http://www.sciencedirect.com/science/article/pii/S0024320513002750>

***论文二***

**论文题目**：

Noninvasive approach to assess coronary artery stenoses and ischemia

**作者及其单位和联系信息**：

Cardiology Department, Tenth People's Hospital, Shanghai, China (Drs Dai and Xu) (xuyaweish@yahoo.com.cn); and Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Dr Xia).

**杂志及论文出版信息**

JAMA. 2013 Jan 16;309(3):235-6. doi: 10.1001/jama.2012.157192**.**

**论文摘要**：

No abstract

**Pubmed链接**：

<http://www.ncbi.nlm.nih.gov/pubmed/23321754>

**论文全文链接**：

<http://jama.jamanetwork.com/article.aspx?articleid=1557727>

**附录二**

**作者个人简介示例 （由作者提供，尽量用150-300英文单词）**

夏华向Harry Hua-Xiang Xia 80级医疗系二大班(E80-2)，85级硕士研究生(G85)（协和医院消化专业）

Dr. Xia obtained his Bachelor and Master degrees in Medicine in 1985 and 1988, respectively, at Tongji Medical University, and practiced as a gastroenterologist at Wuhan Union Hospital, China. Dr. Xia obtained his Ph.D in 1994 and worked as a postdoctoral fellow at Trinity College, Dublin University, Ireland. He spent 5 years as a senior Research Officer at Nepean Hospital, The University of Sydney, Australia, and 6 years as an Assistant Professor at Queen Mary Hospital, The University of Hong Kong to extend his research on *Helicobacter pylori* and associated diseases including gastric cancer, peptic ulcer disease, and gastritis, and achieved academic reputation worldwide in the field. He was elected as a fellow of the American College of Gastroenterology in 2008. He joined Novartis Pharmaceuticals Corporation in 2006 for clinical development of new investigational drugs in different therapeutic areas. So far, he has published over 160 peer-reviewed articles, almost half of which he is the first or corresponding author. He has published one book and is the first author of 10 book chapters. He is now an Editor-in-Chief of *Journal of Clinical & Translational Hepatology* (www.jcthnet.com, 2013–present), and an Associate Editor-in-Chief of *World Journal of Gastroenterology* (2002- present) and *Journal of Interventional Gastroenterology* (2011–present). He used to serve as an editorial board member of *Alimentary Pharmacology Therapeutics* (2005, 2006) and *Journal of Gastroenterology & Hepatology* (2005-2011). He is the founder and an Editor-in-Chief of *Medjaden* Bioscience Limited (www.medjaden.com), an editing company based in Hong Kong and mainland China. He is also a founder of Xia & He Publishing Limited ([www.xiahepublishing.com](http://www.xiahepublishing.com)), the publisher of *Journal of Clinical and Translational Hepatology*, *Exploratory Research and Hypothesis in Medicine* and *Journal of Exploratory Research in Pharmacology*. He is currently an Adjunct Professor, Beijing Friendship Hospital, Capital Medical University, Beijing, Municipal Hospital, Qingdao University, Qingdao, and First Affiliated Hospital, Guangdong Pharmaceutical University, Guangdong, China.